Laurence Torcel-Pagnon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laurence Torcel-Pagnon has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Javier Díez-Domingo
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
2 shared publications - Patrick Mahy
Sciensano, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium
2 shared publications - Simon de Lusignan
Affiliations Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, Royal College of General Practitioners, London, United Kingdom
2 shared publications - Tyra Grove Krause
Epidemiological Infectious Disease Preparedness, Statens Serum Institut , Copenhagen
2 shared publications - Vincent Bauchau
GSK, Av. Fleming 20, 1300 Wavre, Belgium
2 shared publications - Xavier Kurz
European Medicines Agency Amsterdam The Netherlands
2 shared publications
Latest Publications
- Open Access
- 27 October 2022
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 21 (12) , 1701-1710
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative
Fighting pandemics requires an established infrastructure for pandemic preparedness, with existing, sustainable platforms ready to be activated. This includes platforms for disease surveillance, vi...
- 27 October 2022
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 21 (12) , 1701-1710
Open AccessThe value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative
Fighting pandemics requires an established infrastructure for pandemic preparedness, with existing, sustainable platforms ready to be activated. This includes platforms for disease surveillance, vi...
- Open Access
- 25 January 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (3) , 1058
Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies.
- 25 January 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (3) , 1058
Open AccessChallenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies.
- Open Access
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines
- Open Access
Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe